The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/all-aral-treatment-combo-aml-earns-fda-nod-2026a1000foi?src=rss
Author :
Publish date : 2026-05-14 18:15:00
Copyright for syndicated content belongs to the linked Source.